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Chemotherapy during a viable pregnancy may be associated with adverse perinatal outcomes. 
We conducted a prospective cohort study to examine the perinatal outcomes of babies born 
following in-utero exposure to chemotherapy in Australia and New Zealand.  Over 18 months 
we identified 24 births, of >400g and/or >20-weeks gestation to women diagnosed with breast 
cancer in the first or second trimesters. Eighteen babies were exposed in-utero to 
chemotherapy. Chemotherapy commenced at a median of 20 weeks gestation, for a mean 
duration of 10 weeks. Twelve exposed infants were born preterm with 11 by induced labour or 
pre-labour caesarean section. There were no perinatal deaths or congenital malformations. Our 
findings show that breast cancer diagnosed during mid-pregnancy is often treated with 
chemotherapy. Other than induced preterm births, there were no serious adverse perinatal 
outcomes. 




The management of cancer diagnosed during pregnancy poses unique challenges in optimising 
maternal and infant outcomes. One of these challenges is choosing the optimal treatment 
regimen to balance the benefit to the women and the potential risks of adverse outcomes for 
the fetus1. Timing of treatment initiation is also challenging, especially if cancer diagnosis is 
early in the first trimester as fetal exposure to chemotherapy during the period of organogenesis 
has been associated with an increased risk of congenital malformations2,3. 
This study describes the perinatal outcomes of babies of women diagnosed with breast cancer 
during the first or second trimesters of pregnancy by whether exposed to in-utero systemic 
chemotherapy or not. 
Methods: 
A population-based prospective cohort study design was conducted in Australia and New 
Zealand using the Australasian Maternity Outcomes Surveillance System (AMOSS)4. We 
identified babies born to women with a confirmed diagnosis of breast cancer during pregnancy 
through monthly surveillance between January 2013 and June 2014. Eligible births included 
live or stillborn babies of at least 400 grams or 20 weeks gestation whether exposed to 
chemotherapy or not. Data were collected on maternal and cancer care, and perinatal 
outcomes. 
Perinatal outcomes included: stillbirth, neonatal death, major congenital malformations, preterm 
birth (< 37 completed weeks of gestation), low birthweight (< 2,500 grams) and small for 
gestational age  (birthweight < 10th percentile for gestational age)5.  
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Chi-square, Fisher’s exact test, Fisher-Freeman-Halton test, and independent sample t-test 
were used to investigate the difference in outcomes of babies stratified by in-utero exposure to 
chemotherapy. 
Results 
Of the 24 babies born to women diagnosed with breast cancer during the 1st and 2nd trimesters 
of pregnancy, 18 (75%) were exposed to chemotherapy, and six were not (detailed in 
Supplementary Table 1). Demographic and treatment characteristics of the 24 women are 
shown in Supplementary Tables 1 & 2.   
The types of systemic chemotherapeutic agents used during the pregnancies are listed in 
Supplementary Table 3. The median gestational age at first in-utero exposure was 20 weeks 
(range 13 - 31). Fourteen (77.8%) of the 18 babies had their first exposure in the second 
trimester and four (22.2%) in the third trimester. All 18 babies were exposed to a minimum of 
two therapeutic agents with a mean duration of exposure of 10.4 ± 5.8 weeks. All babies were 
exposed to alkylating agents; either nitrogen mustard (Cyclophosphamide) or platinum 
compounds (Carboplatin), 16 (88.9%) were exposed to anthracyclines (Doxorubicin or 
Epirubicin), 10 (55.6%) to taxanes (Paclitaxel or Docetaxel) and 1 (5.6%) to Fluorouracil.  
The mean gestational age at birth for the 18 chemotherapy exposed babies was 35.7 ± 2 weeks, 
significantly lower than that for the six non-exposed babies (mean 38.8 ± 1.5 weeks) (P =0.002) 
(Table 1). There were no stillbirths, diagnosed congenital malformations or neonatal deaths in 
any of the 24 babies. The need for resuscitation was seen in the two babies exposed to 
Tamoxifen combined systemic therapy (Cyclophosphamide, Doxorubicin and Docetaxel and 
Tamoxifen; and Paclitaxel, Carboplatin and Tamoxifen). The former was female born following 
induction at 36 weeks, birthweight 2480 grams Apgar score at 5 minutes of 8 and resuscitated 
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with a continuous positive airway pressure (CPAP) mask, however, discharged home without 
the need for admission to neonatal intensive care (NICU) or Special Care Nursery (SCN).  
 The latter was male delivered at 34 weeks by CS (birthweight 2240 grams, Apgar score at 5 
minutes of 8) and required resuscitation with a continuous positive airway pressure (CPAP) 
mask and admission to the SCN.  
A third baby exposed to Trastuzumab, Docetaxel and Cyclophosphamide was born vaginally 
following induction at 36 weeks (birthweigh 2380 grams; Apgar score of 10) and was admitted 
to SCN with mild respiratory distress before being discharged home on day 4. 
Ten of the babies were exposed to Taxanes in addition to other chemotherapeutic agents. 
However, their perinatal outcomes did not significantly differ from those who had exposed to 
non-Taxane chemotherapy (Supplementary Table 4).   
Discussion: 
In this analysis, we examined the effect of in-utero exposure to chemotherapy on perinatal 
outcomes. As expected, the gestation at diagnosis influenced the decision on the timing of 
chemotherapy and the non-use of radiotherapy during pregnancy. All cases in our study 
whether exposed to chemotherapy or not were diagnosed in the first or second trimesters. The 
other factors influencing management decisions are the grading and staging of breast cancer. 
Of note, none of the non-exposed babies’ mothers had distant metastasis and none had a 
preterm birth.  
It is recognised that management decisions are often a delicate balance in considering the 
treatment impacts on both the maternal and fetal health during the pregnancy. In this study, 
apart from preterm birth, there were no serious adverse perinatal outcomes in the 18 babies 
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exposed to chemotherapy nor in the six non-exposed babies. There was no perinatal death or 
congenital malformations.  
The majority of exposed babies were exposed to cyclophosphamide and doxorubicin, with one 
baby exposed to trastuzumab and two others to tamoxifen. This is consistent with the other 
studies in which the babies were mainly exposed to a combination of cyclophosphamide and 
doxorubicin6-9. 
Tamoxifen is contraindicated during pregnancy10. The two babies who were exposed to 
tamoxifen in our study were born without congenital malformations. However, due to the small 
number of babies exposed to tamoxifen in our study, we were unable to recommend the use of 
tamoxifen during pregnancy.  
Trastuzumab is contraindicated during pregnancy, as it has been associated with 
oligohydramnios and renal impairment in the fetus11. We were unable to confirm this association 
as in our study only one baby was exposed to trastuzumab in the third trimester.  
In agreement with other studies2, our results show a significantly higher rate of preterm births 
among babies exposed to systemic therapy during pregnancy compared to the non-exposed 
babies (12 out of 18 vs 0 out of 6).  
Morbidities in neonates (low birthweight and admission to NICU/SCN) in our study were directly 
linked to preterm birth. Similar to the previous studies2,9, the leading cause of preterm birth 
amongst the exposed group in our study is iatrogenic to facilitate maternal systemic 
chemotherapy postpartum (supplementary figure 1).         
There is growing evidence on the safety of exposure to anthracyclines containing regimens 
after the first trimester; however, it is limited for the other chemotherapeutic agents and the 
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non-chemotherapy systemic treatment. There is a need for standardised information on the 
maternal-fetal exposure and outcomes of chemotherapy and other systemic anticancer agents 
use in pregnancy that is collated internationally into a database for use in informing clinical 
practice and research worldwide. 
A major strength of this cohort study is its population-design of all cases in Australia and New 
Zealand during the study period. Limitations include the rarity of the condition, the low uptake 
of chemotherapy during pregnancy and the follow-up period being restricted to the perinatal 
period.  
Conclusion:  
Our study provides assurance that there were no congenital abnormalities or perinatal deaths 
among the 18 babies exposed to at least two different chemotherapy agents during pregnancy. 
The directionality of our findings is consistent with the two largest studies in the international 
literature, particularly regarding preterm birth6,7. Larger observational studies are needed to 
provide better information on in-utero exposure and outcomes following chemotherapy to inform 
gestational breast cancer management.   
Additional Information: 
• Ethics approval and consent to participate: 
Ethics approval for our study was granted by the NSW Population and Health Services 
Research Ethics Committee (HREC/09/CIPHS/21), and multiple Human Research 
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• Consent for publication: NA  
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Table 1: Perinatal outcomes amongst the 24 babies. 
  Exposed Non-exposed P value 
 (n=18)  (n=6)  
Live births 18(100) 6(100) NA 
Neonatal deaths* 0(0) 0(0) NA 
    
Preterm (<37 weeks)    
Yes 12(66.7) 0(0) 
0.014 <32 weeks 1(5.6) 0(0) 33-<37 weeks 11(61.1) 0(0) 
No 6(33.3) 6(100) 
Small for gestational age 2(11.1) 0(0) 1.000 
Low birthweight (<2500 g) 9(50) 0(0) 0.052 
Resuscitation    
Yes 6(33.3) 0(0) 
0.277 
Neopuff or CPAP mask only 3(16.7) 0(0) 
Oxygen 1(5.6) 0(0) 
Neopuff or CPAP mask + Suction 
+ Oxygen 2(11.1) 0(0) 
No 12(66.7) 6(100) 
Respiratory support    
  Yes** 1(5.6) 0(0) 1.000 No 16(88.9) 6(100) 
Not known 1(5.6) 0(0)  
Apgar score (5 minutes)    
8 5(27.8) 0(0) 
0.348 9 10(55.6) 5(83.3) 
10 3(16.7) 1(16.7) 
Admission to NICU/SCN 9(50) 1(16.7) 0.341 
Breastfeeding initiated    
Yes 6(33.3) 5(83.3) 0.061 No 12(66.7) 1(16.7) 




Supplementary Table 1: Maternal demographics       
 Exposed Non-exposed P value 
  (n=18)  (n=6)  
Country    
Australia 15(83.3) 5(83.3) 1.000 New Zealand 3(16.7) 1(16.7) 
Age (years)    
<35 9(50) 3(50) 1.000 
≥35 9(50) 3(50) 
BMI (kg/m2)    
18.50 - 24.99 12(66.7) 4(66.7) 1.000 
≥25.00 5(27.8) 2(33.3) 
Unknown 1(5.6) 0(0)  
Hospital Sector    
Public 11(61.1) 5(83.3) 0.621 Private 7(38.9) 1(16.7) 
Parity    
0 7(38.9) 4(66.7) 0.357 >1 11(61.1) 2(33.3) 
Smoking status    
Never smoked 9(50) 5(83.3) 
0.319 
Quit smoking before 
becoming pregnant 4(22.2) 0(0) 
Smoking during 
pregnancy  1(5.6) 1(16.7) 
Not known 4(22.2) 0(0)  
ART*     
Yes 0(0) 0(0) N/A No 18(100) 5(83.3) 
Not known 0(0) 1(16.7)  




Supplementary Table 2: Maternal cancer characteristics, tumour treatment and obstetric 
management 
 Exposed Non-exposed P value 
  (n=18)  (n=6)  
Tumour grade    
Low 0(0) 3(50) 
0.030 Intermediate 3(16.7) 0(0) 
High 12(66.7) 3(50) 




Yes 7(38.9) 0(0) 0.123 
  No 9(50) 5(83.3) 
Not known 2(11.1) 1(16.7)  
Estrogen receptor status 
  
 
Positive 12(66.7) 4(66.7) 1.000 
 Negative 5(27.8) 1(16.7) 
Not known 1(5.6) 1(16.7)  
Progestrone receptor status    
Positive 9(50) 4(66.7)  
Negative 8(44.4) 1(16.7) 0.360 
Not known 1(5.6) 1(16.7)  
HER 2 status    
Positive 4(22.2) 0(0) 0.546 Negative 13(72.2) 4(66.7) 




Yes 6(33.3) 0(0) 0.144  No 11(61.1) 6(100) 
Not known 1(5.6) 0(0)  
Surgery During Pregnancy 
  
 
Yes 15(83.3) 5(83.3) 1.000 No, delayed until end of pregnancy 3(16.7) 1(16.7) 
Radiotherapy During Pregnancy 
  
 
No, not recommended 6(33.3) 3(50) 0.635 No, delayed until end of pregnancy 12(66.7) 3(50) 
Postpartum Systemic Therapy 
  
 
Yes 17(94.4) 2(33.3) 0.021 No 1(5.6) 3(50) 
Not known 0(0) 1(16.7)  
Corticosteroid for fetal lung maturity 
  
 
Yes 10(55.6) 0(0) 0.015 No 6(33.3) 6(100) 
Not known 2(11.1) 0(0)  
Induction of labour 
  
 
Yes 10(55.6) 5(83.3) 0.531 No/not applicable 8(44.4) 1(16.7) 
Method of birth 
  
 
Vaginal birth 11(61.1) 4(66.6) 1.000 





Supplementary Table 3: Systemic therapeutic agents during pregnancy. 
 Timing of therapy  
 
2nd Trimester  
(13-27 weeks)  
(n=14) 
3rd Trimester  




 n* (%) n* (%) n* (%) 
Cyclophosphamide    
Yes 13(92.9) 4(100) 17(94.4) 
No 1(7.1) 0(0) 1(5.6) 
Carboplatin    
Yes 1(7.1) 0(0) 1(5.6) 
No 13(92.9) 4(100) 17(94.4) 
Docetaxel    
Yes 2(14.3) 1(25) 3(16.7) 
No 12(85.7) 2(50) 14(77.8) 
Not stated 0(0) 1(25) 1(5.6) 
Doxorubicin    
Yes 12(85.7) 3(75) 15(83.3) 
No 2(14.3) 0(0) 2(11.1) 
Not stated 0(0) 1(25) 1(5.6) 
Epirubicin    
Yes 1(7.1) 0(0) 1(5.6) 
No 13(92.9) 2(50) 15(83.3) 
Not stated 0(0) 2(50) 2(11.1) 
Fluorouracil    
Yes 1(7.1) 0(0) 1(5.6) 
No 13(92.9) 2(50) 15(83.3) 
Not stated 0(0) 2(50) 2(11.1) 
Paclitaxel    
Yes 6(42.9) 1(25) 7(38.9) 
No 8(57.1) 2(50) 10(55.6) 
Not stated 0(0) 1(25) 1(5.6) 
Tamoxifen    
Yes 2(14.3) 0(0) 2(11.1) 
No 12(85.7) 2(50) 14(77.8) 
Not stated 0(0) 2(50) 2(11.1) 
Trastuzumab     
Yes 0(0) 1(25) 1(5.6) 
No 14(100) 2(50) 16(88.9) 
Not stated 0(0) 1(25) 1(5.6) 




Supplementary Table 4: Perinatal outcomes amongst the 18 babies exposed to chemotherapy 
based of their exposure to Taxanes. 
  Taxanes  yes Taxanes no P value 
 (n=10)  (n=8)  
Live births 10(100) 8(100) NA 
Neonatal deaths* 0(0) 0(0) NA 
    
Preterm (<37 weeks)    
Yes 7(70) 5(62.5) 
1.000 <32 weeks 0(0) 1(12.5) 33-<37 weeks 7(70) 4(50) 
No 3(30) 3(37.5) 
Small for gestational age 1(10) 1(12.5) 1.000 
Low birthweight (<2500 g) (0) (0) 1.000 
Resuscitation    
Yes 4(40) 2(25) 
1.000 
Neopuff or CPAP mask only 2(20) 1(12.5) 
Oxygen 1(10) 0(0) 
Neopuff or CPAP mask + Suction 
+ Oxygen 1(10) 1(12.5) 
No 6(60) 6(75) 
Respiratory support    
  Yes** 1(10) 0(0) 1.000 No 9(90) 7(87.5) 
Not known 0(0) 1(12.5)  
Apgar score (5 minutes)    
8 3(30) 2(25) 
0.241 9 4(40) 6(75) 
10 3(30) 0(0) 
Admission to NICU/SCN 5(50) 4(50) 1.000 
Breastfeeding initiated    
Yes 3(30) 3(37.5) 1.000 No 7(70) 5(62.5) 
 
  
Supplementary Figure 1 Mode of birth and postpartum maternal treatment for preterm babies exposed to systemic therapy
 
